论文部分内容阅读
在以往的文献中已经报道过抗精神病药物的使用所带来一些代谢后果,包括体重增加、高血糖和脂代谢紊乱。虽然抗精神病药物所致代谢功能障碍的确切机制不明,但是仍有一些可能的机制。由于体重增加被认为是糖尿病和脂代谢紊乱发展的诱发因素,所以抗精神病药物治疗中监测体重变化是一个重要的筛查措施。由于某些抗精神病药物不太可能造成体重增加,如阿立哌唑和齐拉西酮等,所以对于高风险人群或者之前诊断为糖尿病或者有高血糖、脂代谢紊乱和/或体重显著增加的人群来说,选择低风险的抗精神病药物是一个明智的选择。
In the past literature there have been reported some metabolic consequences of the use of antipsychotics, including weight gain, hyperglycemia, and disorders of lipid metabolism. Although the exact mechanism of anti-psychotic drug-induced metabolic dysfunction is unknown, there are some possible mechanisms. As weight gain is considered as a predisposing factor in the development of disorders of diabetes and lipid metabolism, monitoring body weight changes during antipsychotic drug treatment is an important screening measure. Because certain antipsychotics are less likely to cause weight gain such as aripiprazole and ziprasidone, there is a significant increase in high-risk populations or previously diagnosed diabetes or hyperglycemia, dyslipidemia, and / or weight gain The crowd, the choice of low-risk antipsychotic drugs is a wise choice.